NASDAQ:OGENOragenics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.61 +0.02 (+3.41 %) (As of 05/22/2020 04:00 PM ET) Add Compare Share Today's Range$0.56Now: $0.61▼$0.6250-Day Range$0.39MA: $0.53▼$0.8352-Week Range$0.35Now: $0.61▼$0.88Volume1.67 million shsAverage Volume2.23 million shsMarket Capitalization$33.57 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring chemical agent for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013; a license agreement with LPThera LLC to develop LPT3-04; and a license agreement Texas A&M University System for access to new homologs of the lantibiotic MU1140 and other lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Oragenics. Previous Next 1.9 Community Rank Outperform VotesOragenics has received 19 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOragenics has received 32 “underperform” votes. (Add your “underperform” vote.)Community SentimentOragenics has received 62.75% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Oragenics and other stocks. Vote “Outperform” if you believe OGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOragenics does not currently pay a dividend.Dividend GrowthOragenics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oragenics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OGEN Previous Symbol CUSIPN/A CIKN/A Webwww.oragenics.com Phone813-286-7900Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees6 Outstanding Shares55,363,000Market Cap$33.57 million Next Earnings Date5/25/2020 (Estimated) OptionableNot Optionable NASDAQ:OGEN Rates by TradingView Receive OGEN News and Ratings via Email Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Oragenics (NASDAQ:OGEN) Frequently Asked Questions How has Oragenics' stock been impacted by COVID-19 (Coronavirus)? Oragenics' stock was trading at $0.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OGEN shares have increased by 1.1% and is now trading at $0.6064. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Oragenics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oragenics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Oragenics. When is Oragenics' next earnings date? Oragenics is scheduled to release its next quarterly earnings announcement on Monday, May 25th 2020. View our earnings forecast for Oragenics. Has Oragenics been receiving favorable news coverage? News articles about OGEN stock have trended extremely negative on Monday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Oragenics earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutOragenics. Who are some of Oragenics' key competitors? Some companies that are related to Oragenics include Biopharmx (BPMX), AquaBounty Technologies (AQB), Orthocell (OCC), Cynata Therapeutics (CYP), Oxford Biodynamics (OBD), iShares Diversified Alternatives Trust (ALT), Pediapharm (PDP), 4d Pharma (DDDD), Biotron (BIT), Immunoprecise Antibodies (IPA), Sirona Biochem (SBM), Immutep (IMM), OptiBiotix Health (OPTI), e-Therapeutics (ETX) and Actinium Pharmaceuticals (ATNM). View all competitors. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Ibio (IBIO), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Pharmacyte Biotech (PMCB), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), Digital Ally (DGLY) and Inovio Pharmaceuticals (INO). Who are Oragenics' key executives? Oragenics' management team includes the following people: Dr. Alan F. Joslyn, Pres, CEO & Director (Age 60)Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 63)Dr. Martin Handfield, Sr. VP of Discovery Research (Age 48)Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant What is Oragenics' stock symbol? Oragenics trades on the NASDAQ under the ticker symbol "OGEN." How do I buy shares of Oragenics? Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Oragenics' stock price today? One share of OGEN stock can currently be purchased for approximately $0.61. How big of a company is Oragenics? Oragenics has a market capitalization of $33.57 million. Oragenics employs 6 workers across the globe. What is Oragenics' official website? The official website for Oragenics is www.oragenics.com. How can I contact Oragenics? The company can be reached via phone at 813-286-7900. This page was last updated on 5/25/2020 by MarketBeat.com Staff
